Summit Therapeutics Inc.: shareholders and insiders

SMMTNASDAQHealthcare · Pharmaceutical Preparations

Price

$9.95

November 20, 2026Market cap $7.7B

What Ploutos Investor adds for Summit Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from FY2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 38% since Nov 4, 2026, when the 10-Q these figures come from was filed ($16.17 then, $9.95 on Nov 20, 2026). The figures date from before that move.10-Q

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Nov 20, 2026, from their own Form 4 filings.

11 Form 4s

Insider trades start on October 6, 2020

Until lately Summit Therapeutics was a foreign company listed in the US. Officers of foreign companies do not report their purchases and sales, so there are none before. They are not missing on our side: they were never filed.

  1. Until 2020Foreign company (annual report on 20-F)
  2. March 2021Becomes a US filer (annual report on 10-K)
  3. October 6, 2020The first insider trade report (Form 4)

Bought on the market

$104M

3 people

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $52M by 2 people·no sales

  • 2025: no buys, no sales
  • 2026: bought $52M by 2 people, no sales
  • Nov 20, 2026Robert W DugganCo-Chief Executive Officer
    Kind
  • Nov 20, 2026Mahkam ZanganehCo-Chief Executive Officer
    Kind
  • Nov 16, 2026Robert W DugganCo-Chief Executive Officer
    Kind
  • Nov 16, 2026Mahkam ZanganehCo-Chief Executive Officer
    Kind
  • Nov 16, 2026Manmeet Singh SoniCOO and CFO
    Kind
  • Oct 8, 2026Bhaskar AnandChief Accounting Officer
    Kind
  • Jun 12, 2026Mahkam ZanganehCo-Chief Executive Officer
    Kind
  • Jun 12, 2026Robert W DugganCo-Chief Executive Officer
    Kind
  • Jun 4, 2026Robert W DugganCo-Chief Executive Officer
    Kind
  • Jun 4, 2026Mahkam ZanganehCo-Chief Executive Officer
    Kind
  • Jun 4, 2026Manmeet Singh SoniCOO and CFO
    Kind
  • Jun 4, 2026Manmeet Singh SoniCOO and CFO
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade.

Insiders and their shares

Every buy and sale by SMMT's officers and directors from 2020 up to November 21, 2025, 6 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

No filing over 5%

Since Dec 18, 2024 nobody has filed a Schedule 13D or 13G for Summit Therapeutics shares.

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Citadel Advisors (Griffin)
    In the quarter+119%
  • D.E. Shaw
    In the quarter+69%
  • AQR Capital
    In the quarter+263%
  • Point72 (Cohen)
    In the quarter-99%
  • Millennium Mgmt (Englander)
    In the quarter-90%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 5.27% of its shares outstanding were held short, -0.6% since the report before.

Shares held short
40.90M
5.27%
Since the report before41.16M on Sep 30, 2026
-0.6%
7.0
5.82M
More days to cover thanof 4,578 US-listed companies with enough volume
78%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 9.48M
  • Nov 15, 2023: Shares held short 10.00M
  • Nov 30, 2023: Shares held short 10.04M
  • Dec 15, 2023: Shares held short 9.44M
  • Dec 29, 2023: Shares held short 9.79M
  • Jan 12, 2024: Shares held short 10.82M
  • Jan 31, 2024: Shares held short 11.30M
  • Feb 15, 2024: Shares held short 12.75M
  • Feb 29, 2024: Shares held short 15.95M
  • Mar 15, 2024: Shares held short 16.96M
  • Mar 28, 2024: Shares held short 21.81M
  • Apr 15, 2024: Shares held short 22.90M
  • Apr 30, 2024: Shares held short 23.40M
  • May 15, 2024: Shares held short 22.57M
  • May 31, 2024: Shares held short 21.26M
  • Jun 14, 2024: Shares held short 23.43M
  • Jun 28, 2024: Shares held short 20.31M
  • Jul 15, 2024: Shares held short 18.63M
  • Jul 31, 2024: Shares held short 17.79M
  • Aug 15, 2024: Shares held short 17.26M
  • Aug 30, 2024: Shares held short 18.23M
  • Sep 13, 2024: Shares held short 20.73M
  • Sep 30, 2024: Shares held short 16.34M
  • Oct 15, 2024: Shares held short 15.45M
  • Oct 31, 2024: Shares held short 17.04M
  • Nov 15, 2024: Shares held short 15.99M
  • Nov 29, 2024: Shares held short 16.84M
  • Dec 13, 2024: Shares held short 17.53M
  • Dec 31, 2024: Shares held short 19.94M
  • Jan 15, 2025: Shares held short 21.52M
  • Jan 31, 2025: Shares held short 20.86M
  • Feb 14, 2025: Shares held short 21.45M
  • Feb 28, 2025: Shares held short 21.63M
  • Mar 14, 2025: Shares held short 21.22M
  • Mar 31, 2025: Shares held short 23.77M
  • Apr 15, 2025: Shares held short 25.09M
  • Apr 30, 2025: Shares held short 27.19M
  • May 15, 2025: Shares held short 25.73M
  • May 30, 2025: Shares held short 24.44M
  • Jun 13, 2025: Shares held short 30.53M
  • Jun 30, 2025: Shares held short 27.05M
  • Jul 15, 2025: Shares held short 28.56M
  • Jul 31, 2025: Shares held short 30.99M
  • Aug 15, 2025: Shares held short 29.81M
  • Aug 29, 2025: Shares held short 29.72M
  • Sep 15, 2025: Shares held short 32.21M
  • Sep 30, 2025: Shares held short 35.93M
  • Oct 15, 2025: Shares held short 32.27M
  • Oct 31, 2025: Shares held short 32.44M
  • Nov 14, 2025: Shares held short 31.24M
  • Nov 28, 2025: Shares held short 32.35M
  • Dec 15, 2025: Shares held short 35.75M
  • Dec 31, 2025: Shares held short 37.01M
  • Jan 15, 2026: Shares held short 37.20M
  • Jan 30, 2026: Shares held short 36.96M
  • Feb 13, 2026: Shares held short 37.87M
  • Feb 27, 2026: Shares held short 34.67M
  • Mar 13, 2026: Shares held short 36.12M
  • Mar 31, 2026: Shares held short 34.56M
  • Apr 15, 2026: Shares held short 34.50M
  • Apr 30, 2026: Shares held short 29.19M
  • May 15, 2026: Shares held short 29.82M
  • May 29, 2026: Shares held short 36.13M
  • Jun 15, 2026: Shares held short 36.81M
  • Jun 30, 2026: Shares held short 39.86M
  • Jul 15, 2026: Shares held short 37.33M
  • Jul 31, 2026: Shares held short 36.25M
  • Aug 14, 2026: Shares held short 37.43M
  • Aug 31, 2026: Shares held short 41.33M
  • Sep 15, 2026: Shares held short 41.08M
  • Sep 30, 2026: Shares held short 41.16M
  • Oct 15, 2026: Shares held short 40.90M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading48.9% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 48.9% of the shares in the reported trades were short sales, against 57.1% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
48.9%
The 14 beforeOct 14, 2026 – Nov 2, 2026
57.1%
Change
-8.2 pts
Short sales a dayon average, of 3.33M shares
1.63M
More than atof 3,666 US-listed companies, same days
44%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 51.1%
  • Oct 15, 2026: Short sales 64.3%
  • Oct 16, 2026: Short sales 56.1%
  • Oct 19, 2026: Short sales 56.1%
  • Oct 20, 2026: Short sales 59.9%
  • Oct 21, 2026: Short sales 74.3%
  • Oct 22, 2026: Short sales 51.9%
  • Oct 23, 2026: Short sales 59.7%
  • Oct 26, 2026: Short sales 54.5%
  • Oct 27, 2026: Short sales 47.4%
  • Oct 28, 2026: Short sales 45.8%
  • Oct 29, 2026: Short sales 57.5%
  • Oct 30, 2026: Short sales 49%
  • Nov 2, 2026: Short sales 58.6%
  • Nov 3, 2026: Short sales 56.7%
  • Nov 4, 2026: Short sales 56.5%
  • Nov 5, 2026: Short sales 54.1%
  • Nov 6, 2026: Short sales 50.8%
  • Nov 9, 2026: Short sales 44.3%
  • Nov 10, 2026: Short sales 57.8%
  • Nov 11, 2026: Short sales 51.5%
  • Nov 12, 2026: Short sales 60.7%
  • Nov 13, 2026: Short sales 50%
  • Nov 16, 2026: Short sales 42.8%
  • Nov 17, 2026: Short sales 36.6%
  • Nov 18, 2026: Short sales 57.4%
  • Nov 19, 2026: Short sales 50.9%
  • Nov 20, 2026: Short sales 48.7%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

1.26B Insiders' shares162.18% Of the company
  • Robert W DugganCo-Chief Executive Officer
    Directly585M
  • Mahkam ZanganehCo-Chief Executive Officer
    Directly36.93M
  • Yu XiaDirector
    Directly–
  • Manmeet Singh SoniCOO and CFO
    Directly3.22M
  • Ankur DhingraChief Financial Officer
    Directly–
  • Bhaskar AnandChief Accounting Officer
    Directly261.0K

A lower bound: it counts only the 6 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

25 ETFs holding it1.01% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund1.01%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.67%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.15%
  • IWPiShares Russell Mid-Cap Growth ETF
    Weight in the fund0.05%
  • SCHMSchwab U.S. Mid-Cap ETF
    Weight in the fund0.04%
  • VBRVanguard Small-Cap Value Index Fund
    Weight in the fund0.04%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund0.03%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.03%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.02%
  • ONEQFidelity Nasdaq Composite Index ETF
    Weight in the fund0.02%

25 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

242 Managers, Q2 2026$2.0B Value of their positions
  • Q3 2025: Managers 233
  • Q4 2025: Managers 207
  • Q1 2026: Managers 225
  • Q2 2026: Managers 242

Institutional investors by quarter

The fund managers holding SMMT, quarter by quarter, from Q1 2015 to Q2 2025, 42 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 242 managers held 136M shares, worth $2.0B. During the quarter 57 opened a position, 40 closed one, 96 added and 56 trimmed.

The largest holders, Q2 2026

  • Baker Bros. Advisors
    In the quarter-9.9%
  • FMR
    In the quarter-7.5%
  • State Street
    In the quarter+36%
  • BlackRock
    In the quarter-1.3%
  • Vanguard Capital Management
    In the quarter+0.4%
  • UBS Group
    In the quarter+42%
  • Vanguard Portfolio Management
    In the quarter-3.7%
  • Goldman Sachs Group
    In the quarter×14.5
  • Price T Rowe Associates
    In the quarter-53%
  • Point72 (Cohen)
    In the quarter+372%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Summit Therapeutics's filings show?

Who buys and sells is one part of Summit Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about SMMT's shareholders

Didn't find what you were looking for?

Ask us
Have SMMT's insiders bought or sold?

From Jun 4, 2026 to Nov 20, 2026 Summit Therapeutics's insiders bought $104M and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.

Which well-known managers hold SMMT?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $64M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.